Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

The MarketWatch News Department was not involved in the creation of this content.-- Commercial sponsorship integrates EvE Bio's growing field--defining "pharmome" map - 385,572 ri ...

In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics ...

Traditionally, developing a new drug can take over a decade, but AI technology is changing that timeline. Major pharmaceutical companies like Pfizer and AstraZeneca are leveraging AI to accelerate the ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...

Lab testing giant ALS has surfed a boom in minerals testing to produce a strong interim result, despite a drug assay downturn ...

Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were announced this week, ...

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), a clinical-stage innovative drug development ...

The company, which had no revenue last year and $5.1 million in sales for the first nine months of this year with widening ...

EFEC’s visit to Jiangbei New Area revealed not only a thriving industrial cluster but also a deeper shift — a new stage in ...

Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, ...